• Most Popular
  • Most Shared

AVI BioPharma's genetic disorder drug gets fast-track status

Mon Dec 3, 2007 9:30am EST

Stocks

   

Dec 3 (Reuters) - AVI BioPharma Inc (AVII.O) said U.S. regulators granted fast-track status to its experimental drug AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder that affects children.

The company plans to initiate a clinical trial for the drug, which was recently granted orphan drug status, by mid-2008 to evaluate its safety and potential efficacy in ambulatory DMD patients, AVI BioPharma said in a statement. (Reporting by Shikhar Balwani in Bangalore; Editing by Anupama Dwivedi)



More from Reuters

A Greenpeace activist dressed as one of the "Four Horsemen of the Apocalypse" rides outside the parliament building during a brief protest in Copenhagen December 13, 2009. REUTERS/Christian Charisius

The face of climate protest

Protesters around the globe called for an end to global warming as climate talks in Copenhagen entered their sixth day.  Video 

    Climate conference
    President Barack Obama (R) meets with financial services industry leaders in the Roosevelt Room of the White House in Washington December 14, 2009. REUTERS/Larry Downing

    Obama takes "fat cats" to task

    Backed by Americans outraged by multi-billion dollar bailouts, President Obama met with a dozen of Wall Street's top bankers in a bid to crack down on the so-called "fat cats" largely held responsible for the financial crisis.  Full Article 

    Executive Compensation
    Lockheed Martin Chief Executive Robert Stevens answers a question during the Reuters Aerospace and Defense Summit in Washington December 14, 2009. REUTERS/Molly Riley

    Lockheed eyes deals

    The future demands of cybersecurity make that sector one of many the aerospace giant sees as an acquisition target in the coming year.  Full Article 

    Aerospace and Defense Summit